-
Mashup Score: 1
Approximately 80% of all breast cancers (BCs) are currently categorized as human epidermal growth factor receptor 2 (HER2)-negative [immunohistochemistry (IHC) 0, 1+, or 2+/in situ hybridization (ISH) negative]; approximately 60% of BCs traditionally categorized as HER2-negative express low levels of HER2. HER2-low (IHC 1+ or IHC 2+/ISH−) status became clinically actionable with approval of trastuzumab deruxtecan to treat unresectable/metastatic HER2-low BC. Greater understanding of patients with HER2-low disease is urgently needed.
Source: www.esmoopen.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
PURPOSE Trastuzumab-containing chemotherapy is the recommended first-line regimen for human epidermal growth factor receptor 2 (HER2)–positive advanced gastric or gastroesophageal junction (G/GEJ) cancer. We evaluated the safety and efficacy of trastuzumab combined with ramucirumab and paclitaxel as second-line treatment for HER2-positive G/GEJ cancer. PATIENTS AND METHODS Patients with HER2-positive advanced G/GEJ cancer who progressed after first-line treatment with trastuzumab-containing chemotherapy were enrolled from five centers in the Republic of Korea. Patients were administered a 28-day cycle of trastuzumab (once on days 1, 8, 15, and 22: 2 mg/kg followed by 4 mg/kg loading dose), ramucirumab (once on days 1 and 15: 8 mg/kg), and paclitaxel (once on days 1, 8, and 15: dose level 1, 80 mg/m2; or dose level -1, 70 mg/m2). Phase II was conducted with the recommended phase II dose (RP2D). Primary end points were determination of RP2D during phase Ib and investigator-assessed progr
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors - 10 month(s) ago
Key Points. The combinatorial dual-epitope DC vaccine is safe.This vaccine regimen induced an immune response in a minority of patients.One patient had an excep
Categories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0HER2+ Early-Stage Breast Cancer Roundtable: Standard of Care and Alternative Options for Breast Cancer Management - 10 month(s) ago
This video highlights the current guideline recommendations for treating early breast cancer as well as the current guidelines for metastatic breast cancer.
Source: Consultant360Categories: General Medicine News, Latest HeadlinesTweet-
Now is your chance to hear the latest insights on treating #BreastCancer from experts in the field! Watch our latest sponsored discussion, HER2+ #earlystagebreastcancer Roundtable: Standard of Care and Options for Breast Cancer Management: https://t.co/Hm0dVMy0XQ #oncology #HER2 https://t.co/VdIOyHSsBG
-
-
Mashup Score: 0
SPONSORED In this roundtable discussion, 4 renowned leaders in the breast cancer space share exclusive experiences and information on how they counsel their patients through a breast cancer diagnosis, highlight current guideline recommendations for treating early versus metastatic breast cancer, identify factors that guide their treatment approach, and also weigh the benefits of quicker treatment…
Source: Consultant360Categories: General Medicine News, Latest HeadlinesTweet-
Sponsored: Get the latest insights on #HER2+ #earlystagebreastcancer from 4 renowned oncologists! Learn how they counsel their patients & follow current guidelines to give the best care. Stay tuned for new videos being released! #breastcancer #oncology https://t.co/JXGOgc0dOe https://t.co/SJUmPAlTPd
-
-
Mashup Score: 0
Background Human epidermal growth factor receptor 2 (HER2) targeted therapy combined with endocrine therapy has been recommended as an alternative treatment strategy for patients with hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (MBC). This study aimed to evaluate the role of pyrotinib, an oral pan-HER irreversible tyrosine kinase inhibitor, in combination with letrozole…
Source: BioMed CentralCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2-positive breast cancer - 11 month(s) ago
AbstractBackground. Programmed cell death–1 (PD-1) and programmed cell death–ligand 1 (PD-L1) inhibitors have poor efficacy in patients with trastuzumab-resista
Source: OUP AcademicCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0In TNBC, repeated biopsies may reveal emergent HER2-low expression - 11 month(s) ago
Results could broaden eligibility for treatment with the antibody-drug conjugate trastuzumab deruxtecan.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer - npj Precision Oncology - 11 month(s) ago
Despite decades of study, the molecular mechanisms and selectivity of the biomolecular components of honeybee (Apis mellifera) venom as anticancer agents remain largely unknown. Here, we demonstrate that honeybee venom and its major component melittin potently induce cell death, particularly in the aggressive triple-negative and HER2-enriched breast cancer subtypes. Honeybee venom and melittin…
Source: NatureCategories: Healthcare Professionals, Latest HeadlinesTweet
-
Mashup Score: 5Breast Cancer - 11 month(s) ago
Breast Cancer
Source: ASCOCategories: Latest Headlines, Oncologists2Tweet-
RT @ASCO: Just issued: New ASCO and @Pathologists guideline update on #HER2 testing in #BreastCancer. Read more: https://t.co/19eZWWQj2V #b…
-
Important and very timely data: Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of #HER2-low #breastcancer. Recently published in @ESMO_Open https://t.co/MtkELiVF2X